<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04887324</url>
  </required_header>
  <id_info>
    <org_study_id>RC21_0188</org_study_id>
    <nct_id>NCT04887324</nct_id>
  </id_info>
  <brief_title>Real-life Data of Constitutional Von Willebrand Disease in Western France</brief_title>
  <acronym>HOPSCOTCH-II</acronym>
  <official_title>Real-life Data of Constitutional Von Willebrand Disease in Western France: Treatment Outcomes With the Recombinant Von Willebrand Factor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this observational study HOPSCOTcH-WILL II is to provide an accurate and&#xD;
      detailed account of current Von Willebrand Disease (VWD) therapeutic management by collecting&#xD;
      real-life data on hemorrhagic treated events in the 5 Western French Hemophilia Treatment&#xD;
      Center.&#xD;
&#xD;
      The HOPSCOTCH-WILL II study aims to describe therapeutic management of patients with VWD,&#xD;
      following the provision of a recombinant drug in France; It will also permit to carry out a&#xD;
      budget impact analysis to quantify the economic significance of this new era.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Observational study, description of the global therapeutic modalities required for severe treated hemorrhagic events in constitutional Von Willebrand Disease patients of any severity</measure>
    <time_frame>4 years</time_frame>
    <description>Data collection for evaluation of Clotting factors quantities used by collection of treatments for severe hemorrhagic events</description>
  </primary_outcome>
  <enrollment type="Anticipated">1030</enrollment>
  <condition>Von Willebrand Diseases</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Constitutional Von Willebrand Disease patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Constitutional Von Willebrand Disease patient, of any severity, with or without Von&#xD;
             Willebrand Factors inhibitors&#xD;
&#xD;
          -  Patient included in the research database BERHLINGO&#xD;
&#xD;
          -  Patient treated or not by desmopressin or Von Willebrand Factor/FVIII/by-passing&#xD;
             agents available on the French market (at baseline)&#xD;
&#xD;
          -  Patient who agrees to participate in the HOPSCOTcH-Will II and followed in one of the&#xD;
             5 investigator centers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Patients under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marc Trossaert</last_name>
    <phone>0240087468</phone>
    <email>marc.trossaert@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc Trossaert</last_name>
      <phone>0240087468</phone>
      <email>marc.trossaert@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 15, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

